What explains the differences between centres in the European screening trial? A simulation study by Nevalainen, Jaakko et al.
Cancer Epidemiology 46 (2017) 14–19What explains the differences between centres in the European
screening trial? A simulation study
Jaakko Nevalainena,*, Ulf-Håkan Stenmanb, Teuvo L. Tammelac, Monique Roobold,
Sigrid Carlssone,f, Kirsi Talalag, Fritz H. Schröderd, Anssi Auvinena
aUniversity of Tampere, School of Health Sciences, Tampere, Finland
bDepartment of Clinical Chemistry, Helsinki University Central Hospital, Finland
c Tampere University Hospital, Department of Urology and University of Tampere, Medical School, Tampere, Finland
dDepartment of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
e Sahlgrenska Academy at Göteborg University, Gothenburg, Sweden
fMemorial Sloan-Kettering Cancer Centre, Department of Surgery and Department of Epidemiology and Biostatistics, New York, NY, USA
g Finnish Cancer Registry, Helsinki, Finland
A R T I C L E I N F O
Article history:
Received 8 August 2016
Received in revised form 4 November 2016
Accepted 13 November 2016







A B S T R A C T
Background: The European Randomised study of Screening for Prostate Cancer (ERSPC) is a multicentre,
randomised screening trial on men aged 55–69 years at baseline without known prostate cancer (PrCa) at
randomisation to an intervention arm invited to screening or to a control arm. The ERSPC has shown a
significant 21% reduction in PrCa mortality at 13 years of follow-up. The effect of screening appears to
vary across centres, for which several explanations are possible. We set to assess if the apparent
differences in PrCa mortality reduction between the centres can be explained by differences in screening
protocols.
Methods: We examined the centre differences by developing a simulation model and estimated how
alternative screening protocols would have affected PrCa mortality.
Results: Our results showed outcomes similar to those observed, when the results by centres were
reproduced by simulating the screening regimens with PSA threshold of 3 versus 4 ng/ml, or screening
interval of two versus four years. The findings suggest that the differences are only marginally
attributable to the different screening protocols.
Conclusion: The small screening impact in Finland was not explained by the differences in the screening
protocols. A possible reason for it was the contamination of and the unexpectedly low PrCa mortality in
the Finnish control arm.
ã 2016 Elsevier Ltd. All rights reserved.
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The European Randomised study of Screening for Prostate
Cancer (ERSPC) is a multicentre, randomised screening trial
assessing mortality from prostate cancer (PrCa) in an intervention
arm invited to prostate-specific antigen (PSA)-based screening
compared with a control arm without intervention. The trial was
initiated in 1993–1996 in seven European countries (N = 162,243):
the Netherlands, Sweden and Finland (responsible for 78% of the
total number of men included), and smaller centres in Switzerland,
Belgium, Italy and Spain. In an updated analysis, the ERSPC has* Corresponding author at: School of Health Sciences, 33014, University of
Tampere, Finland.
E-mail address: jaakko.nevalainen@uta.fi (J. Nevalainen).
http://dx.doi.org/10.1016/j.canep.2016.11.005
1877-7821/ã 2016 Elsevier Ltd. All rights reserved.recently shown a significant 21% reduction in PrCa mortality at
13 years of follow-up [1].
Interestingly, the screening effect does not appear to be
constant across the trial centres, with the largest reduction in
PrCa mortality in Sweden, followed by the Netherlands and a non-
significant 10% decrease in Finland [1–4].
We aim to assess if, and to what extent, the apparent differences
in PrCa mortality reduction between the centres can be explained
by differences in screening protocols. Both Netherlands and
Sweden used a PSA threshold of 3 ng/ml as indication for prostate
biopsy, while in Finland it was set at 4 ng/ml (with an ancillary test
at PSA 3.0–3.9 ng/ml). The screening interval was four years in
Finland and the Netherlands, and two years in Sweden. Although
PSA is measured in screening at regular intervals in accordance
with centre-specific protocols, the PSA level is known to increase
with age and any prostate disease. Thus, a screen-positive man
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earlier time, but this remains unobservable until the protocol-
scheduled measurement. The time to detection of an elevated PSA
affects the probability of developing advanced disease and the risk
increases with less frequent screening or a higher PSA threshold,
which may in turn increase PrCa mortality and reduce the
screening effect.
To assess the impact of the screening regimen on screening
outcomes, we developed a longitudinal model for PSA and a
simulation model for the prediction of PrCa death under different
hypothetical conditions. The joint use of these two models allowed
estimation of the effects of different screening protocols on PrCa
mortality in three largest ERSPC centres.
2. Materials and methods
2.1. Data sets analysed
The present analysis was based on 126,829 men aged
55–69 years at baseline without known PrCa at randomisation
from the Netherlands, Sweden and Finland, including 55,199 men
assigned to the intervention arm. The follow-up time was
truncated at 12 years, during which 5565 (10.1%) men were
diagnosed with PrCa in the intervention and 4777 (6.7%) in the
control arm. A total of 252 (0.4%) men in the intervention arm and
426 (0.6%) men in the control arm died from PrCa. The median age
of the participants at randomisation was 59 years, but the
Netherlands centre comprised older men (median age 62 years)
than those in Sweden and Finland. Full ERSPC study details are
given in Schröder et al. [1].
2.2. Statistical methods
We (i) developed and fitted a longitudinal model on PSA
depicting the continuous PSA development over time (velocity or
doubling time) in men with and without PrCa and (ii) using the
estimated PSA levels, simulated the screening and PrCa outcomes
under various hypothetical screening protocols. For example, a
simulation following the Swedish protocol at all centres should
show the potential effect of a two-year screening interval, i.e. to
what extent the differences are attributable to the frequency of
screening.
The model for PSA development was built and estimated on PSA
data obtained in the ERSPC study, and the same data was used to
interpolate/predict individual development of PSA. More specifi-
cally, a linear mixed model was fitted for PSA (transformed as log
[PSA + 1]) to depict the continuous PSA development of each man
with at least one PSA measurement. The fixed effect part of the
model consisted of linear and quadratic age, and of an assumed
change in the quadratic part five years before the diagnosis of PrCa.
The change was allowed to vary according to the Gleason score (<7,
7 or >7) of the PrCa. Thus, the individual profiles consisted of
piecewise exponential components estimated from the data,
allowing a rapid increase starting five years before the diagnosis
of PrCa. The choice of five years was based on initial empirical
investigation of the data, choosing alternative annual change
points and taking the change point which fitted the data best. Man-
specific random effects were introduced for the intercept, linear
and quadratic terms in the model to realistically capture
observable deviations from the mean profile and to account for
the natural heterogeneity in the population, and hence, the
covariance structure. Based on the individual-specific fitted PSA
curves, we estimated the change in PSA concentration for men
from randomization up to PrCa diagnosis or 12 years of follow-up,
whichever came first. By generating the PSA histories, we could
estimate the time when a man with a PrCa would enter thedetectable preclinical phase of the disease, i.e. the cancer become
potentially detectable by screening and when the hypothetical
screening protocol would have been able to detect the elevated
PSA, resulting in detection of the cancer by screening (diagnosis
and subsequent commencement of treatment).
The simulation model for PrCa mortality was built sequentially.
First, we estimated the probability of PrCa death during the first
two years after randomization. Second, among those who survived
the first two years, we estimated the probability of PrCa death
between two and four years. Following this sequential construc-
tion, a set of probabilities was estimated from the data up to the
last interval from 10 to 12 years. As multiple time intervals were
obtained on the same individuals, these probabilities were
estimated by using generalized estimating equations models with
a complementary log-log link function including baseline age,
centre, time interval, estimated log of PSA at the beginning of the
time interval, and finally, information on whether the individual
was screen-positive at the beginning of the time interval, as
covariates. Men with no PSA measurements (non-participants and
control arm) were not included in the estimation of the model
parameters.
Once the set of probabilities was established, we simulated
hypothetical data by bootstrap resampling from this model under
the following scenarios:
 The Swedish screening protocol with two-year screening
interval addressing whether PrCa mortality in the screening
arms of the Netherlands and Finland would have been improved
relative to the control arm. In this scenario, the Finnish
individuals would have become screen positive earlier as the
delay to reach the threshold of 3 ng/ml would have been shorter
due to more frequent screening and lower threshold, and the
Dutch men due shorter screening interval.
 No screening-scenario expected to result in similar PrCa
mortality in the intervention and the control arms. This means
that men would have never become screen positive, regardless of
the longitudinal development of PSA. The scenario was intended
to show whether the effects of screening have been correctly
estimated by the simulation model.
 Simulation with similar procedures as actually applied in each
centre. This was used as a second validation of the simulation
model expected to yield results similar to those actually
observed.
Men in the control arm in each centre were used as observed,
without simulation.
The times of death overall were assumed to be uniformly
distributed on the time interval when PrCa death occurred.
The simulation model is particularly designed for ERSPC and
addressing the current research question and is similar to the
FHCRC model in the implementation of PSA model part (https://
resources.cisnet.cancer.gov/registry/packages/psapc-fhcrc/). Full
details are given in the Appendix.
3. Results
The PSA model indicated statistically significant differences
between the centres, with the highest levels in Finland, followed
by Sweden and the Netherlands in that order (Table A.2). The linear
component for age in the model indicated a steady increase in the
average PSA levels with a quadratic age component depicting a
small, but statistically significant deceleration in the velocity. Men
with Gleason score >7 tumors showed the largest acceleration in
the PSA development five years prior to the actual diagnosis, but
substantial changes were also observed in men with Gleason score
7 or <7 cancers. The random effects part of the model (not shown)
Fig. 1. Cumulative hazard of prostate cancer in the intervention arm, control arm and simulated arms under the Swedish screening protocol.
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the importance of predicting the PSA at different times with a
delicate balance between observed individual data and the average
PSA development for similar men (Figure A.1).
Fig. 1 shows the Nelson-Aalen estimates of the cumulative
hazard of PrCa death for the hypothetical intervention arm, if the
Swedish protocol would have been applied in all of the centres, as
well as the observed cumulative hazard for the actual intervention
and control arms. Unsurprisingly, there would have been no
change in PrCa mortality in Sweden, because the hypothetical
intervention arm was constructed under the screening protocol
used in Sweden. The hypothetical intervention arms for the
Netherlands and Finland indicate that screening every two years
with a lower PSA threshold than was used in Finland would have
affected PrCa mortality only slightly, as the estimated cumulative
hazards of the hypothetical intervention arms improved very little
compared to the actual results based on the observed data in the
intervention arms. Moreover, the observed cumulative hazards, for
instance at 10 years, were 0.00334 in the Netherlands and
0.00359 in Finland, i.e. close to the midpoints of the 95% confidence
intervals (CI) of the cumulative hazards of the hypothetical
(simulated) intervention arms. The symmetric CI (0.00230–
0.00391 in the Netherlands and 0.00276–0.00402 in Finland) also
indicates consistency of the actual screening outcomes and those
obtained using a hypothetical alternative screening algorithm,
pointing to only a small contribution of the simulated screening
features.
Table 1 shows the results in terms of observed and simulated
PrCa mortality in the intervention arm. The median number of PrCa
deaths in Finland across simulations was 151, slightly higher thanTable 1
Observed and simulation-based prediction of PrCa mortality by centre due to the impl
Observed data Model simula
Centre Number of
PrCa deaths




Finland 148 346,038 0.43 151 (142–160)
The Netherlands 73 189,685 0.38 76 (71–82) 
Sweden 31 64,489 0.48 32 (27–35) 
a Medians and interquartile ranges (IQR) were computed across the simulated data the observed 148 PrCa deaths, with comparable PrCa mortality
rates (0.43 and 0.40 per 1000 person-years). Similarly, the
observed and simulated PrCa mortality rates in the Netherlands
were closely smilar, 0.38 and 0.37. Also the ratio of observed and
simulated mortality were close to one, the confidence intervals
covering unity (with a wide margin on both sides) and perfectly in
line with Fig. 1, providing supportive evidence that the difference
between the screening protocols (as captured by the simulation)
explains only a small part of the difference between the centres.
Fig. 2 (top row) shows that the simulation model reconstructed
the observed data of the intervention arm with high agreement
with the ERSPC screening protocols. The graphs in the bottom row
of Fig. 2 shows that the model, and the screening effects within it,
represent well the risk in the absence of screening, because the
hypothetical “intervention” arms without screening closely
matched the observed control arms both in Sweden and the
Netherlands. During the first five to six years of follow-up, the PrCa
mortality in the actual control arm in the Netherlands was lower
than observed in the intervention arm and obtained by the
simulation model for the hypothetical non-screened intervention
arm. However, the PrCa mortality in the control arm caught up
with the simulated intervention arm without screening, and
behaved thereafter as predicted by the simulation model. Finland
showed a completely different pattern: observed PrCa mortality in
the control arm was consistently lower than predicted by the
simulation of the hypothetical intervention arm in the absence of
screening.
In a model-based simulation, assuming that 20% of the men in
the control arm would have received similar screening as in the
intervention arm (“effective contamination”) and 80% of the menementation of the Swedish screening protocol within each centre.




of person years (IQR)a






0.40 (0.34–0.46) 0.92 (0.78–1.07)
207,588
(207,552–207,623)
0.37 (0.29–0.45) 0.96 (0.76–1.17)
70,673
(70,652–70,692)
0.45 (0.31–0.62) 0.93 (0.65–1.30)
sets within each centre.
Fig. 2. Model validation results. Top row of plots shows that the simulation model is able to produce consistent data to what was actually observed (the simulated
intervention arm vs. the intervention arm) under the ERSPC screening protocols. The bottom row shows the expected results in absence of screening.
J. Nevalainen et al. / Cancer Epidemiology 46 (2017) 14–19 17remained unscreened, resulted in similar PrCa mortality to what
was observed at 12 years (Fig. 3).
4. Discussion
The study hypothesis that the differences between ERSPC study
centres were due to differences in screening protocols was not
supported by the findings of the present simulation study. Only
marginal additional PrCa mortality reduction could have been
obtained in Finland and in the Netherlands by implementing the
Swedish screening protocol. The finding is in line with two recent
modelling studies [5,6], which found small differences in PrCa
mortality between alternative screening strategies. Wu et al. [7]
suggested that the PrCa mortality reduction could be more
substantial with shorter interscreening intervals.
Based on the simulation, the PrCa mortality in the Finnish
control arm is lower than expected in the absence of any screening.Fig. 3. Model-based simulation assessing the impact of adding organized screenThe observation was detected only in Finland, but not in Sweden or
the Netherlands. Together with a slightly less effective screening
protocol, this accounts for the smaller relative screening effect in
Finland. The most likely explanation for the lower-than-expected
PrCa mortality in the Finnish control arm is contamination, i.e.
opportunistic PSA testing among men in the control arm.
The evidence for opportunistic screening in the Finnish control
arm is sparse. Ten percent of men in the screening arm have
previously reported having a PSA test before the first screening
round of the trial [8]. In a survey of attitudes among Finnish
physicians, the frequency of reported regular PSA testing among
asymptomatic men declined from 18% to 9% between 1999 and
2007 [9]. More recently, it has been estimated that 50% of the men
in the control arm in Finland have been tested at least once in the
first eight years of follow-up (unpublished data). Such a high
contamination rate in the control arm is bound to reduce the
difference in PrCa mortality between the screening and controling to the hypothetical control arm without any screening (“0% screening”).
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database for the Nordic countries (http://www.dep.iarc.fr/NORD-
CAN/English/frame.as), PrCa mortality in Finland in 2012 was
22.1 and in Sweden 29.9 in Sweden per 100,000 man-years. The
clearly lower PrCa mortality in Finland supports this interpreta-
tion. During the conduct of ERSPC, PrCa mortality in Finland has
declined from 18.7 in 1992-96 to 12.6 in 2012 (Finnish Cancer
Registry, Cancer Statistics at www.cancerregistry.fi). NORDCAN
figures are age-adjusted to European standard population and
Finnish Cancer Registry figures are age-adjusted to world standard
population. In the United States, Etzioni et al. [10] have suggested
that, in addition to PSA screening, improvements in treatment have
contributed to the decline in PrCa mortality.
Based on case-control studies, the evidence of the effect of
unorganized screening by PSA and/or digital rectal examination on
PrCa mortality is not consistent [11–15]. Ecological studies also
show contradictory results [16–18].
In a recent comparison, the Swedish control arm of ERSPC
showed no PrCa mortality improvement to pre-PSA era historical
population data [19]. The extent of contamination in the Swedish
control arm is unknown, however. It has also been estimated that
noncompliance and contamination dilute the screening effect from
a relative risk of PrCa mortality from 0.49 to 0.68 in the Dutch
centre of the ERSPC [20].
Thus, effectiveness of opportunistic screening remains open,
and is very likely to be inferior to an organised screening
programme. Hence, a PrCa mortality reduction equivalent to
20% of the men being included in a screening programme in the
control arm offers an underestimate of the extent of contamina-
tion. In reality, a larger proportion of men were probably tested,
with gradual introduction and less systematic referral to diagnostic
examinations leading to a similar number of cases receiving early
treatment, as if 20% were screened in accordance with a rigorous
protocol. Nevertheless, the 20% is very close to the published
estimate of contamination in the Finnish control arm at four years.
However, in the light of the controversial evidence on the effect
of unorganized and opportunistic screening, other explanations for
the smaller screening benefit in Finland, such as differences in
number of screens, proportion of positive tests or procedures taken
based on PSA tests, are also possible.
The simulation proved to be realistic and useful in assessing the
differences between the studycentres. Aweakness of the model is that
the PrCa diagnosis was only indirectly incorporated in the simulation
model, by elevation of the PSA levels prior to the diagnosis. We could
not reliably evaluate how more frequent screening would influence
the number of cancers detected and the timing of the diagnosis
without imposing restrictive and uncertain assumptions. Such
assumptions could not have been verified and would have had a
substantial effect on the results. They were therefore not introduced,
but left as an indirect component. The simulation proved realistic and
sensitive, and is potentially useful for estimation of effects of
alternative screening protocols elsewhere as well.
These results indicate that opportunistic screening dilutes the
screening effects on PrCa mortality in the Finnish centre. As
Finland is the largest single centre in ERSPC, maximal efficiency of
PrCa screening is most likely to be greater than has been reported
in ERSPC, provided that there are no other factors which may
influence outcomes in Finland. ERSPC is likely to be affected by
contamination, though unlikely as strongly as PLCO [21].
New insights from the current study should be considered
when revising the recommendations on PSA based PrCa screening.
Choice between PSA cut-off (3 vs 4 ng/ml) and screening interval
(2 vs 4 years) do not seem to be major determinants of screening
effect, and therefore less intensive screening algorithm in these
respects may be preferred to reduce costs and adverse effects
(overdiagnosis). Prevalence of opportunistic screening, on theother hand, should be considered when assessing the expected
effect of prostate cancer screening.
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